Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?
Open Access
- 1 July 2004
- Vol. 53 (7), 919-921
- https://doi.org/10.1136/gut.2003.036400
Abstract
New corticotropin releasing factor (CRF) antagonists in irritable bowel disease (IBS) warrant testing, and CRF1 receptors may be a promising target for the treatment of IBS.Keywords
This publication has 44 references indexed in Scilit:
- Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndromeGut, 2004
- CRF receptor type 1 and 2 expression and anatomical distribution in the rat colonJournal of Neurochemistry, 2004
- Role of peripheral CRF signalling pathways in stress‐related alterations of gut motility and mucosal functionNeurogastroenterology & Motility, 2004
- Nibbling at CRF receptor control of feeding and gastrocolonic motilityTrends in Pharmacological Sciences, 2003
- Brain Penetrance, Receptor Occupancy and Antistress In Vivo Efficacy of a Small Molecule Corticotropin Releasing Factor Type I Receptor Selective AntagonistNeuropsychopharmacology, 2002
- Role of Stress in Functional Gastrointestinal DisordersDigestive Diseases, 2001
- Neuropsychiatric Effects and Type of IFN-α in Chronic Hepatitis CJournal of Interferon & Cytokine Research, 2001
- Local production of corticotropin releasing hormone is increased in experimental intestinal inflammation in rats.Gut, 1996
- Effects of the corticotropin‐releasing factor (CRF) on rectal afferent nerves in humansNeurogastroenterology & Motility, 1996
- Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis.Gut, 1995